Distillery spotlight: new Type II diabetes mechanisms from academia

While the incretin paradigm will remain center stage in Type II diabetes R&D for a while to come, it’s clear there’s room for other pathways to offer solutions. New studies highlight options outside of incretin for stimulating insulin secretion, as well as other mechanisms for improving how pancreatic islet cells function, and how their signals are received.

The dominance of incretin therapies has raised the barrier to entry for new mechanisms in Type II diabetes, both because of their effectiveness against the disease itself, and their benefits in combating comorbidities including obesity, cardiovascular events, metabolic dysfunction-associated steatohepatitis (MASH) and chronic kidney disease. ...